Antiviral Inhibition of the HIV-1 capsid protein

Chun Tang, Erin Loeliger, Isaac Kinde, Samson Kyere, Keith Mayo, Eric Barklis, Yongnian Sun, Mingjun Huang, Michael F. Summers

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

During the assembly stage of the human immunodeficiency virus (HIV) replication cycle, several thousand copies of the viral Gag polyprotein associate at the cell membrane and bud to form an immature, non-infectious virion. Gag is subsequently cleaved by the protease, which liberates the capsid proteins for assembly into the polyprotein shell of the central core particle (or capsid) of the mature virus. Viral infectivity is critically dependent on capsid formation and stability, making the capsid protein a potentially attractive antiviral target. We have identified compounds that bind to an apical site on the N-terminal domain of the HIV-1 capsid protein and inhibit capsid assembly in vitro. One compound, N-(3-chloro-4-methylphenyl)-N′-{2-[({5-[(dimethylamino)-methyl]-2- furyl}-methyl)-sulfanyl]ethyl}urea) (CAP-1), is well tolerated in cell cultures, enabling in vivo antiviral and mechanistic studies. CAP-1 inhibits HIV-1 infectivity in a dose-dependent manner, but does not interfere with viral entry, reverse transcription, integration, proteolytic processing, or virus production, indicating a novel antiviral mechanism. Significantly, virus particles generated in the presence of CAP-1 exhibit heterogeneous sizes and abnormal core morphologies, consistent with inhibited CA-CA interactions during virus assembly and maturation. These findings lay the groundwork for the development of assembly inhibitors as a new class of therapeutic agents for the treatment of AIDS.

Original languageEnglish (US)
Pages (from-to)1013-1020
Number of pages8
JournalJournal of Molecular Biology
Volume327
Issue number5
DOIs
StatePublished - Apr 11 2003

Fingerprint

Capsid
Capsid Proteins
Antiviral Agents
HIV-1
Virion
Viruses
gag Gene Products
Virus Assembly
Polyproteins
Virus Replication
Reverse Transcription
Acquired Immunodeficiency Syndrome
Peptide Hydrolases
Cell Culture Techniques
Cell Membrane
HIV
Therapeutics

Keywords

  • Antiviral inhibitors
  • Capsid assembly
  • HIV-1
  • Nuclear magnetic resonance

ASJC Scopus subject areas

  • Virology

Cite this

Tang, C., Loeliger, E., Kinde, I., Kyere, S., Mayo, K., Barklis, E., ... Summers, M. F. (2003). Antiviral Inhibition of the HIV-1 capsid protein. Journal of Molecular Biology, 327(5), 1013-1020. https://doi.org/10.1016/S0022-2836(03)00289-4

Antiviral Inhibition of the HIV-1 capsid protein. / Tang, Chun; Loeliger, Erin; Kinde, Isaac; Kyere, Samson; Mayo, Keith; Barklis, Eric; Sun, Yongnian; Huang, Mingjun; Summers, Michael F.

In: Journal of Molecular Biology, Vol. 327, No. 5, 11.04.2003, p. 1013-1020.

Research output: Contribution to journalArticle

Tang, C, Loeliger, E, Kinde, I, Kyere, S, Mayo, K, Barklis, E, Sun, Y, Huang, M & Summers, MF 2003, 'Antiviral Inhibition of the HIV-1 capsid protein', Journal of Molecular Biology, vol. 327, no. 5, pp. 1013-1020. https://doi.org/10.1016/S0022-2836(03)00289-4
Tang, Chun ; Loeliger, Erin ; Kinde, Isaac ; Kyere, Samson ; Mayo, Keith ; Barklis, Eric ; Sun, Yongnian ; Huang, Mingjun ; Summers, Michael F. / Antiviral Inhibition of the HIV-1 capsid protein. In: Journal of Molecular Biology. 2003 ; Vol. 327, No. 5. pp. 1013-1020.
@article{0e16d0b2a7454edab4abfa1a724be422,
title = "Antiviral Inhibition of the HIV-1 capsid protein",
abstract = "During the assembly stage of the human immunodeficiency virus (HIV) replication cycle, several thousand copies of the viral Gag polyprotein associate at the cell membrane and bud to form an immature, non-infectious virion. Gag is subsequently cleaved by the protease, which liberates the capsid proteins for assembly into the polyprotein shell of the central core particle (or capsid) of the mature virus. Viral infectivity is critically dependent on capsid formation and stability, making the capsid protein a potentially attractive antiviral target. We have identified compounds that bind to an apical site on the N-terminal domain of the HIV-1 capsid protein and inhibit capsid assembly in vitro. One compound, N-(3-chloro-4-methylphenyl)-N′-{2-[({5-[(dimethylamino)-methyl]-2- furyl}-methyl)-sulfanyl]ethyl}urea) (CAP-1), is well tolerated in cell cultures, enabling in vivo antiviral and mechanistic studies. CAP-1 inhibits HIV-1 infectivity in a dose-dependent manner, but does not interfere with viral entry, reverse transcription, integration, proteolytic processing, or virus production, indicating a novel antiviral mechanism. Significantly, virus particles generated in the presence of CAP-1 exhibit heterogeneous sizes and abnormal core morphologies, consistent with inhibited CA-CA interactions during virus assembly and maturation. These findings lay the groundwork for the development of assembly inhibitors as a new class of therapeutic agents for the treatment of AIDS.",
keywords = "Antiviral inhibitors, Capsid assembly, HIV-1, Nuclear magnetic resonance",
author = "Chun Tang and Erin Loeliger and Isaac Kinde and Samson Kyere and Keith Mayo and Eric Barklis and Yongnian Sun and Mingjun Huang and Summers, {Michael F.}",
year = "2003",
month = "4",
day = "11",
doi = "10.1016/S0022-2836(03)00289-4",
language = "English (US)",
volume = "327",
pages = "1013--1020",
journal = "Journal of Molecular Biology",
issn = "0022-2836",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Antiviral Inhibition of the HIV-1 capsid protein

AU - Tang, Chun

AU - Loeliger, Erin

AU - Kinde, Isaac

AU - Kyere, Samson

AU - Mayo, Keith

AU - Barklis, Eric

AU - Sun, Yongnian

AU - Huang, Mingjun

AU - Summers, Michael F.

PY - 2003/4/11

Y1 - 2003/4/11

N2 - During the assembly stage of the human immunodeficiency virus (HIV) replication cycle, several thousand copies of the viral Gag polyprotein associate at the cell membrane and bud to form an immature, non-infectious virion. Gag is subsequently cleaved by the protease, which liberates the capsid proteins for assembly into the polyprotein shell of the central core particle (or capsid) of the mature virus. Viral infectivity is critically dependent on capsid formation and stability, making the capsid protein a potentially attractive antiviral target. We have identified compounds that bind to an apical site on the N-terminal domain of the HIV-1 capsid protein and inhibit capsid assembly in vitro. One compound, N-(3-chloro-4-methylphenyl)-N′-{2-[({5-[(dimethylamino)-methyl]-2- furyl}-methyl)-sulfanyl]ethyl}urea) (CAP-1), is well tolerated in cell cultures, enabling in vivo antiviral and mechanistic studies. CAP-1 inhibits HIV-1 infectivity in a dose-dependent manner, but does not interfere with viral entry, reverse transcription, integration, proteolytic processing, or virus production, indicating a novel antiviral mechanism. Significantly, virus particles generated in the presence of CAP-1 exhibit heterogeneous sizes and abnormal core morphologies, consistent with inhibited CA-CA interactions during virus assembly and maturation. These findings lay the groundwork for the development of assembly inhibitors as a new class of therapeutic agents for the treatment of AIDS.

AB - During the assembly stage of the human immunodeficiency virus (HIV) replication cycle, several thousand copies of the viral Gag polyprotein associate at the cell membrane and bud to form an immature, non-infectious virion. Gag is subsequently cleaved by the protease, which liberates the capsid proteins for assembly into the polyprotein shell of the central core particle (or capsid) of the mature virus. Viral infectivity is critically dependent on capsid formation and stability, making the capsid protein a potentially attractive antiviral target. We have identified compounds that bind to an apical site on the N-terminal domain of the HIV-1 capsid protein and inhibit capsid assembly in vitro. One compound, N-(3-chloro-4-methylphenyl)-N′-{2-[({5-[(dimethylamino)-methyl]-2- furyl}-methyl)-sulfanyl]ethyl}urea) (CAP-1), is well tolerated in cell cultures, enabling in vivo antiviral and mechanistic studies. CAP-1 inhibits HIV-1 infectivity in a dose-dependent manner, but does not interfere with viral entry, reverse transcription, integration, proteolytic processing, or virus production, indicating a novel antiviral mechanism. Significantly, virus particles generated in the presence of CAP-1 exhibit heterogeneous sizes and abnormal core morphologies, consistent with inhibited CA-CA interactions during virus assembly and maturation. These findings lay the groundwork for the development of assembly inhibitors as a new class of therapeutic agents for the treatment of AIDS.

KW - Antiviral inhibitors

KW - Capsid assembly

KW - HIV-1

KW - Nuclear magnetic resonance

UR - http://www.scopus.com/inward/record.url?scp=0037432551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037432551&partnerID=8YFLogxK

U2 - 10.1016/S0022-2836(03)00289-4

DO - 10.1016/S0022-2836(03)00289-4

M3 - Article

C2 - 12662926

AN - SCOPUS:0037432551

VL - 327

SP - 1013

EP - 1020

JO - Journal of Molecular Biology

JF - Journal of Molecular Biology

SN - 0022-2836

IS - 5

ER -